

Practical Perspectives on the Current Role of Bispecific Antibodies in the Management of Lymphoma — What Happened at ASH 2025?

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following best describes the 5-year progression-free survival (PFS) rate for patients in a pivotal Phase II study who achieved a complete response with mosunetuzumab for relapsed/refractory (R/R) follicular lymphoma (FL) after 2 or more prior therapies?
 - a. Higher than 25%
 - b. Higher than 50%**
 - c. Higher than 75%
 - d. Higher than 90%
2. In the 3-year follow-up of the Phase III STARGLO trial, the combination of glofitamab and gemcitabine/oxaliplatin resulted in which of the following outcomes in comparison to rituximab with gemcitabine/oxaliplatin for patients with transplant-ineligible R/R diffuse large B-cell lymphoma (DLBCL)?
 - a. Inferior overall survival (OS)
 - b. Noninferior OS
 - c. Significantly improved OS**
 - d. OS has not yet been reported
3. What was the approximate objective response rate in the 3-year follow-up of the Phase II ELM-2 trial of odronextamab monotherapy for patients with R/R DLBCL?
 - a. 50%
 - b. 65%
 - c. 80%**
 - d. 90%
4. The Phase III EPCORE FL-1 trial evaluating epcoritamab, rituximab and lenalidomide versus rituximab and lenalidomide for patients with R/R FL reported which of the following efficacy outcomes with the epcoritamab triplet?
 - a. Inferior independent review committee PFS (IRC-PFS)
 - b. Noninferior IRC-PFS
 - c. Significantly improved IRC-PFS**
 - d. Data have not yet been reported
5. Which of the following adverse events is the most common noted with the combination of glofitamab with golcadomide among patients with R/R B-cell non-Hodgkin lymphoma?
 - a. Cytokine release syndrome
 - b. Headache
 - c. Injection site reaction
 - d. Neutropenia**